EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

Hsiang-Fong Kao; Chia-Chi Lin; James Chih-Hsin Yang

doi:10.2217/fon.13.56

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

Future Oncol. 2013 Jul;9(7):991-1003. doi: 10.2217/fon.13.56.

Authors

Hsiang-Fong Kao¹, Chia-Chi Lin, James Chih-Hsin Yang

Affiliation

¹ Department of Oncology, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.

PMID: 23837762
DOI: 10.2217/fon.13.56

Abstract

Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Drug Resistance, Neoplasm
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / genetics
ErbB Receptors / immunology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Mutation
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*

Substances

Antibodies, Monoclonal
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors